Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth K Tanabe

Showing results (21-30 of 205) with videos related to

Pageof 21
Sort By:
Hepatobiliary Surgery and Nutrition|February 7, 2024
Scoring microvascular invasion in hepatocellular carcinoma: are we meeting the grade?Derek J Erstad, Kenneth K Tanabe
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 2, 2013
"Infectious" optimism for treatment of hepatocellular carcinomaKenneth K Tanabe, E Antonio Chiocca
Annals of Surgical Oncology|March 7, 2021
ASO Author Reflections: Variations and Inconsistencies in the Guidelines for the Clinical Management of CholangiocarcinomaZhi Ven Fong, Kenneth K Tanabe
Cancer|June 6, 2014
The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and reviewZhi Ven Fong, Kenneth K Tanabe
Annals of Surgical Oncology|April 8, 2010
Creating and providing predictions of melanoma outcomeKenneth K Tanabe, Sebastian Jara, James Michaelson
Hepatology (Baltimore, Md.)|May 7, 2014
Reply: To PMID 24677197Bryan C Fuchs, Yujin Hoshida, Kenneth K Tanabe
Current Cancer Drug Targets|March 10, 2007
HSV-1 viral oncolysis and molecular imaging with PETDarshini Kuruppu, Jon D Dorfman, Kenneth K Tanabe
Hepatobiliary Surgery and Nutrition|June 9, 2016
STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCCSarani Ghoshal, Bryan C Fuchs, Kenneth K Tanabe
Journal of Hepatology|October 4, 2011
Genomic risk of hepatitis C-related hepatocellular carcinomaYujin Hoshida, Bryan C Fuchs, Kenneth K Tanabe
Current Cancer Drug Targets|August 10, 2012
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesYujin Hoshida, Bryan C Fuchs, Kenneth K Tanabe
Pageof 21

Showing results (21-30 of 205) with videos related to

Sort By:
Pageof 21
Hepatobiliary Surgery and Nutrition|February 7, 2024
Scoring microvascular invasion in hepatocellular carcinoma: are we meeting the grade?Derek J Erstad, Kenneth K Tanabe
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 2, 2013
"Infectious" optimism for treatment of hepatocellular carcinomaKenneth K Tanabe, E Antonio Chiocca
Annals of Surgical Oncology|March 7, 2021
ASO Author Reflections: Variations and Inconsistencies in the Guidelines for the Clinical Management of CholangiocarcinomaZhi Ven Fong, Kenneth K Tanabe
Cancer|June 6, 2014
The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and reviewZhi Ven Fong, Kenneth K Tanabe
Annals of Surgical Oncology|April 8, 2010
Creating and providing predictions of melanoma outcomeKenneth K Tanabe, Sebastian Jara, James Michaelson
Hepatology (Baltimore, Md.)|May 7, 2014
Reply: To PMID 24677197Bryan C Fuchs, Yujin Hoshida, Kenneth K Tanabe
Current Cancer Drug Targets|March 10, 2007
HSV-1 viral oncolysis and molecular imaging with PETDarshini Kuruppu, Jon D Dorfman, Kenneth K Tanabe
Hepatobiliary Surgery and Nutrition|June 9, 2016
STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCCSarani Ghoshal, Bryan C Fuchs, Kenneth K Tanabe
Journal of Hepatology|October 4, 2011
Genomic risk of hepatitis C-related hepatocellular carcinomaYujin Hoshida, Bryan C Fuchs, Kenneth K Tanabe
Current Cancer Drug Targets|August 10, 2012
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesYujin Hoshida, Bryan C Fuchs, Kenneth K Tanabe
Pageof 21